Back to Search
Start Over
Pretreated EGFRdel19/BRAFV600Elung adenocarcinoma with leptomeningeal disease achieving long-lasting disease control on Osimertinib, Dabrafenib, and Trametinib: a case report
- Source :
- JTO Clinical and Research Reports; 20230101, Issue: Preprints
- Publication Year :
- 2023
-
Abstract
- Oncogene-addicted non-small cell lung cancer (NSCLC) inevitably becomes resistant to targeted therapy, by developing acquired resistance (AR), on- or off-target mechanisms, potentially detectable by liquid biopsy (LB). We present the first reported case of a pretreated EGFRdel19/BRAFV600Elung adenocarcinoma patient with symptomatic leptomeningeal metastasis (LM) obtaining durable clinical benefit on Osimertinib, Dabrafenib, and Trametinib treatment.
Details
- Language :
- English
- ISSN :
- 26663643
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- JTO Clinical and Research Reports
- Publication Type :
- Periodical
- Accession number :
- ejs63444113
- Full Text :
- https://doi.org/10.1016/j.jtocrr.2023.100545